267 related articles for article (PubMed ID: 24920522)
1. Preclinical formulations: insight, strategies, and practical considerations.
Shah SM; Jain AS; Kaushik R; Nagarsenker MS; Nerurkar MJ
AAPS PharmSciTech; 2014 Oct; 15(5):1307-23. PubMed ID: 24920522
[TBL] [Abstract][Full Text] [Related]
2. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z
Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102
[TBL] [Abstract][Full Text] [Related]
3. A Relative Permittivity Approach for Fast Drug Solubility Screening of Solvents and Excipients in Lipid-Based Delivery.
Niederquell A; Dujovny G; Probst SE; Kuentz M
J Pharm Sci; 2019 Oct; 108(10):3457-3460. PubMed ID: 31255684
[TBL] [Abstract][Full Text] [Related]
4. Recent advances and novel strategies in pre-clinical formulation development: an overview.
Shah AK; Agnihotri SA
J Control Release; 2011 Dec; 156(3):281-96. PubMed ID: 21763367
[TBL] [Abstract][Full Text] [Related]
5. Physical formulation approaches for improving aqueous solubility and bioavailability of ellagic acid: A review.
Nyamba I; Lechanteur A; Semdé R; Evrard B
Eur J Pharm Biopharm; 2021 Feb; 159():198-210. PubMed ID: 33197529
[TBL] [Abstract][Full Text] [Related]
6. Developing early formulations: practice and perspective.
Li P; Zhao L
Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive assessment of ADMET risks in drug discovery.
Wang J
Curr Pharm Des; 2009; 15(19):2195-219. PubMed ID: 19601823
[TBL] [Abstract][Full Text] [Related]
8. Impact of preformulation on drug development.
Bharate SS; Vishwakarma RA
Expert Opin Drug Deliv; 2013 Sep; 10(9):1239-57. PubMed ID: 23534681
[TBL] [Abstract][Full Text] [Related]
9. Development of Cordycepin Formulations for Preclinical and Clinical Studies.
Lee JB; Adrower C; Qin C; Fischer PM; de Moor CH; Gershkovich P
AAPS PharmSciTech; 2017 Nov; 18(8):3219-3226. PubMed ID: 28560504
[TBL] [Abstract][Full Text] [Related]
10. Mitigating Cocrystal Physical Stability Liabilities in Preclinical Formulations.
Bhardwaj S; Lipert M; Bak A
J Pharm Sci; 2017 Jan; 106(1):31-38. PubMed ID: 27665129
[TBL] [Abstract][Full Text] [Related]
11. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
O'Driscoll CM; Griffin BT
Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
[TBL] [Abstract][Full Text] [Related]
12. Preclinical dose number and its application in understanding drug absorption risk and formulation design for preclinical species.
Wuelfing WP; Daublain P; Kesisoglou F; Templeton A; McGregor C
Mol Pharm; 2015 Apr; 12(4):1031-9. PubMed ID: 25671350
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations.
Beg S; Swain S; Rizwan M; Irfanuddin M; Malini DS
Curr Drug Deliv; 2011 Nov; 8(6):691-702. PubMed ID: 21864253
[TBL] [Abstract][Full Text] [Related]
14. Approaches for the development of solid and semi-solid lipid-based formulations.
Jannin V; Musakhanian J; Marchaud D
Adv Drug Deliv Rev; 2008 Mar; 60(6):734-46. PubMed ID: 18045728
[TBL] [Abstract][Full Text] [Related]
15. Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects.
Cherniakov I; Domb AJ; Hoffman A
Expert Opin Drug Deliv; 2015 Jul; 12(7):1121-33. PubMed ID: 25556987
[TBL] [Abstract][Full Text] [Related]
16. Vehicle selection for nonclinical oral safety studies.
Thackaberry EA
Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1635-46. PubMed ID: 24074031
[TBL] [Abstract][Full Text] [Related]
17. Hot-Melt Extrusion: from Theory to Application in Pharmaceutical Formulation.
Patil H; Tiwari RV; Repka MA
AAPS PharmSciTech; 2016 Feb; 17(1):20-42. PubMed ID: 26159653
[TBL] [Abstract][Full Text] [Related]
18. [Enhancing of drug bioavailability using liquisolid system formulation].
Gajdziok J; Vraníková B
Ceska Slov Farm; 2015 Jun; 64(3):55-66. PubMed ID: 26400228
[TBL] [Abstract][Full Text] [Related]
19. Liquisolid systems and aspects influencing their research and development.
Vraníková B; Gajdziok J
Acta Pharm; 2013 Dec; 63(4):447-65. PubMed ID: 24451071
[TBL] [Abstract][Full Text] [Related]
20. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs.
Kawakami K
Adv Drug Deliv Rev; 2012 May; 64(6):480-95. PubMed ID: 22265844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
